ERBB2 and cancer: Since PI3K mutations in HER2-positive tumors is an important determinant of resistance to anti HER2 therapy Trastuzumab [45], we next tested the ability of PP to kill such resistant cancer cells compared with Trastuzumab alone or in combination.